



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Bozenna Dembowska-Baginska**

Organisation/Company: The Children's Memorial Health Institute

Country: Poland

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

Period	Company	Products	Therapeutic Indication
09/2010-08/2019	Roche	Bevacizumab	Metastatic soft tissue sarcoma in children

Classified as public by the European Medicines Agency

01/2015-01/2016	Guerbet	DOTAREM	imaging contrast agent for use with magnetic resonance
07/2016-07/2017	Pierre Fabre	Propranolol	Infantile hemangioma
11/2017-07/2020	BMS	Nivolumab, Ipilimumab	High Grade Primary CNS Malignancies
10/2018-02/2019	Merck Sharp & Dohme Corp (MSD)	Pembrolizumab	Melanoma
06/2015-11/2018	TEVA	Lipegfilgrastim	Neutropenia in children undergoing anticancer chemotherapy
06/2016-03/2017	TEVA	TBO Filgrastim	Neutropenia in children undergoing myelosuppressive chemotherapy
02/2016-02/2017	MSD	Fosaprepitant	Prevention of nausea and vomiting in children undergoing emetogenic chemotherapy
01/2019-11/2020	GUERBET	GDX-44-007	imaging contrast agent used with magnetic resonance in children
10/2015-11/2017	MSD	Fosaprepitant	Prevention of nausea and vomiting in children undergoing emetogenic chemotherapy (phase 4)
07/2020-10/2021	Eisai LTD	Eribulin mesilate	Refractory or recurrent solid tumors in children
06/2022-(current)	GUERBET	GDX 44-015	imaging contrast agent used with magnetic resonance in children

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

Period	Products	Therapeutic Indication	Involvement in the repurposing
01/2014-12/2019	rapamycin	epilepsy	Involvement of my organisation in the repurposing of a medicinal product where the organisation is acting as the champion of the repurposing or is collaborating with the champion of the repurposing, but where I as an individual am not involved in the repurposing
02/2015-11/2020	rituximab	MS	Involvement of my organisation in the repurposing of a medicinal product where the organisation is acting as the champion of the repurposing or is collaborating with the champion of the repurposing, but where I as an individual

Classified as public by the European Medicines Agency

			am not involved in the repurposing
01/2020-(current)	Acetaminophen	Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen	Involvement of my organisation in the repurposing of a medicinal product where the organisation is acting as the champion of the repurposing or is collaborating with the champion of the repurposing, but where I as an individual am not involved in the repurposing

2.10 Any other interests or facts

publicly funded project involving pharmaceutical products- funded by Polish Medical Research Agency

DIPGEN ? Multicenter, open label study using molecularly determined targeted therapies in children 3-18 years of age with DIPG (diffuse intrinsic pontine glioma - DIPG)

publicly funded project involving pharmaceutical products- funded by Polish Medical Research Agency - Open, randomized phase II study assessing safety and efficacy of rapamycin in the treatment of high grade glioma in children. BraimTOR-ONKO

2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

Classified as public by the European Medicines Agency

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Bozenna Dembowska-Baginska
Date:	2022-11-15

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template